Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.

Argyrios ChronopoulosElisa HuynhAgharza AshurovJames S SchutzJost B JonasLars-Olof Hattenbach

Published in: European journal of ophthalmology (2023)

Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.

Keyphrases

age related macular degeneration
vascular endothelial growth factor
endothelial cells
diabetic retinopathy